1
|
Blairon L, Tré-Hardy M, Collignon S, Coenen F, Beukinga I, Cupaiolo R. Added value of a connected glucose meter for glycorrhachia assessment. Pract Lab Med 2024; 39:e00384. [PMID: 38463197 PMCID: PMC10924199 DOI: 10.1016/j.plabm.2024.e00384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Revised: 02/27/2024] [Accepted: 02/29/2024] [Indexed: 03/12/2024] Open
Abstract
Objectives The aim of this study was to demonstrate the performance and added value of rapid glucose determination in cerebrospinal fluid using a connected glucometer. Design and Methods Intra-assay and inter-assay accuracies were calculated using residual clinical samples. Accuracies were measured by comparing the results obtained with the glucometer to those from the central laboratory on a large routine chemistry platform. Results The intra-assay coefficients of variation were between 6.1% and 6.2% for low values (18 mg/dL) and between 5.6% and 6.8% for high values (58 mg/dL). The inter-assay coefficients of variation were between 9.4% and 16.3% for the low values (18 mg/dL) and between 5.7% and 8.7% for the high values (pool; ±75 mg/dL). The regression equation by comparison to the central laboratory was y = 4.08 + 0.82 x, with a coefficient of determination (r2) of 0.95. Conclusions The measurement of glycorrhachia with a connected glucometer before the analysis in the central laboratory allows a rapid orientation in the deferential diagnosis of a meningitis of viral vs bacterial origin. The response time is fast (6 s) and requires only a small amount of fluid (1.2 μL), which is important in infants, especially since lumbar puncture is an integral part of the investigation of the origin of a fever in this population.
Collapse
Affiliation(s)
- Laurent Blairon
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Marie Tré-Hardy
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
- Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium
- Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Belgium
| | - Sophie Collignon
- Department of Emergency Medicine, Iris Hospitals South, Brussels, Belgium
| | - François Coenen
- Department of Emergency Medicine, Iris Hospitals South, Brussels, Belgium
| | - Ingrid Beukinga
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Roberto Cupaiolo
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| |
Collapse
|
2
|
Riahi N, Tré-Hardy M, Hernando C, Blairon L, Cupaiolo R, Beukinga I. Monocytes warning for malaria. Br J Haematol 2024; 204:379-380. [PMID: 38111310 DOI: 10.1111/bjh.19259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2023]
Affiliation(s)
- Nada Riahi
- Department of Laboratory Medicine, Hôpitaux Iris Sud, Brussels, Belgium
| | - Marie Tré-Hardy
- Department of Laboratory Medicine, Hôpitaux Iris Sud, Brussels, Belgium
- Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium
- Department of Pharmacy, Namur Research Institute for Life Sciences, Université de Namur, Namur, Belgium
| | - Carmen Hernando
- Department of Laboratory Medicine, Hôpitaux Iris Sud, Brussels, Belgium
| | - Laurent Blairon
- Department of Laboratory Medicine, Hôpitaux Iris Sud, Brussels, Belgium
| | - Roberto Cupaiolo
- Department of Laboratory Medicine, Hôpitaux Iris Sud, Brussels, Belgium
| | - Ingrid Beukinga
- Department of Laboratory Medicine, Hôpitaux Iris Sud, Brussels, Belgium
| |
Collapse
|
3
|
Debuysschere C, Blairon L, Cupaiolo R, Beukinga I, Tré-Hardy M. Clinical evaluation of a dermatophyte RT-PCR assay and its impact on the turn-around-time: A prospective study. Med Mycol 2023; 61:myad078. [PMID: 37505466 DOI: 10.1093/mmy/myad078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2023] [Revised: 07/25/2023] [Accepted: 07/27/2023] [Indexed: 07/29/2023] Open
Abstract
Onychomycosis is an important public health problem whose prevalence continues to grow and impact public health at several levels. Nevertheless, today the main diagnostic methods used in routine practice have many drawbacks. The aim of this study was to evaluate, for the first time, the clinical performance of a new multiplex polymerase chain reaction (PCR) (Novaplex®) in the identification of the causative agent on nail samples, and its impact on the turnaround time, compared to our traditional laboratory methods. From June 2022 to December 2022, all nail samples sent to our laboratory for suspected onychomycosis were included in this prospective study. We collected for each sample the results obtained with the Novaplex® PCR method and with the traditional direct microscopy examination and culture. Each discordant result was checked using a third method, which is another PCR method (DermaGenius® kit) as a resolver. For culture-positive samples, a turnaround time was calculated and compared to the one obtained with the Novaplex® method. A total of 131 samples were included. Among them, 5 were positive (3.8%) on direct microscopy, 33 were positive (25.2%) after culture, and 98 were negative (74.8%). All positive (n = 33) and negative (n = 69) cultures were also positive/negative with the Novaplex® PCR. Twenty-nine samples were positive with the Novaplex® method but negative with culture (discordant results). The percentage agreement between the culture and the Novaplex® methods was 77.9% (102 out of 131). While tested with the resolver (DermaGenius® PCR), 28 out of 29 discordant results were similarly found positive. The percentage agreement between the two PCR methods (Novaplex® and DermaGenius®) was 96.6%. The Novaplex® PCR method evaluated proved to be very reliable and allowed the direct identification of 62 out of 131 positive samples (47.3%) with the following distribution: 79.0% of Trichophyton rubrum complex, 11.3% of Trichophyton mentagrophytes complex, 6.5% of both Trichophyton rubrum complex and Trichophyton mentagrophytes complex, and 3.2% of Candida albicans. The median time [± 95% CI] for positive culture (between incubation and validation of the final identification) was 15 [12-23] days, while the turnaround time for the Novaplex® method adapted to our clinical laboratory routine is ≤7 days. Laboratory confirmation of onychomycosis is crucial and should always be obtained before starting treatment. The evaluated PCR method offered a rapid, reliable, robust, and inexpensive method of identification of the causative agent compared to traditional methods.
Collapse
Affiliation(s)
- Cyril Debuysschere
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Laurent Blairon
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Roberto Cupaiolo
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Ingrid Beukinga
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Marie Tré-Hardy
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
- Faculty of Medicine, Université libre de Bruxelles, Brussels, Belgium
- Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Namur, Belgium
| |
Collapse
|
4
|
Mbouche P, Blairon L, Cupaiolo R, Zaouak Y, Hainaux B, Beukinga I, Tré-Hardy M. Enterococcus thailandicus, an unusual pathogen in humans encountered in an intra-abdominal infection. New Microbes New Infect 2023; 53:101137. [PMID: 37179572 PMCID: PMC10172700 DOI: 10.1016/j.nmni.2023.101137] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Accepted: 04/20/2023] [Indexed: 05/15/2023] Open
Affiliation(s)
- Patricia Mbouche
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Laurent Blairon
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Roberto Cupaiolo
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Yasmine Zaouak
- Department of Radiology, Iris Hospitals South, Brussels, Belgium
| | - Bernard Hainaux
- Department of Radiology, Iris Hospitals South, Brussels, Belgium
| | - Ingrid Beukinga
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Marie Tré-Hardy
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
- Faculty of Medicine, Université libre de Bruxelles, Brussels, Belgium
- Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Namur, Belgium
| |
Collapse
|
5
|
Tré-Hardy M, De Rauw K, Blairon L, Simon A, Piérard D. Nursery outbreak caused by enteroaggregative Escherichia coli serogroup O111:H21. APMIS 2023; 131:206-216. [PMID: 36799765 DOI: 10.1111/apm.13301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2023] [Accepted: 02/10/2023] [Indexed: 02/18/2023]
Abstract
This study describes, for the first time, the occurrence of an epidemic of enteroaggregative Escherichia coli (EAEC) O111:H21 in a Belgian nursery and describes a practical approach concerning its management. Few data exist in the literature on this type of outbreak. Clinical and microbiological investigations were needed to find a link between the cases and identify the causative agent. The microbiological procedure followed was first based on conventional analyses: isolation using selective cultures, identification by MALDI-TOF MS, antibiogram, determination of the serogroup by agglutination, then whole genome sequencing. A total of 7/21 children were infected with this pathogen. Four cases could be confirmed by a molecular technique, wgMLST, as belonging to the same bacterial clone. The action plan put in place focused on symptomatic case eviction, strict general hygiene precaution as well as specific cleaning and disinfection measures. The epidemic did last only a few days. It appears important, in the context of an epidemic, that clinical laboratories standardize their practice by equipping themselves with molecular techniques such as a multiplex which does not focus only on the serotype O157:H7 and which make it possible to distinguish the different pathotypes of E. coli by targeting several virulence genes (stx, aggR…). However, cost/effectiveness studies are awaited to confirm the interest of a systematic search by molecular method for the pathogen involved in a suspected outbreak occurring in a nursery.
Collapse
Affiliation(s)
- Marie Tré-Hardy
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium.,Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium.,Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Namur, Belgium
| | - Klara De Rauw
- Department of Microbiology, General Hospital AZ Sint-Lucas, Ghent, Belgium
| | - Laurent Blairon
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Anne Simon
- Department of Infection Control, Centre Hospitalier Jolimont-Lobbes, La Louvière, Belgium
| | - Denis Piérard
- Department of Microbiology and Infection Control, Belgian National Reference Center (NRC) for VTEC/STEC, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium
| |
Collapse
|
6
|
Debuysschere C, Beukinga I, Hernando C, Blairon L, Tré-Hardy M, Cupaiolo R. Atypical lymphocytes associated with monkeypox virus infection. Br J Haematol 2022; 199:306. [PMID: 36128942 DOI: 10.1111/bjh.18480] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Revised: 09/12/2022] [Accepted: 09/14/2022] [Indexed: 11/02/2022]
Affiliation(s)
- Cyril Debuysschere
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium.,Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium
| | - Ingrid Beukinga
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Carmen Hernando
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Laurent Blairon
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Marie Tré-Hardy
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium.,Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium.,Department of Pharmacy, Namur Research Institute for Life Sciences, Université de Namur, Namur, Belgium
| | - Roberto Cupaiolo
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| |
Collapse
|
7
|
Tré-Hardy M, Piteüs S, Beukinga I, Blairon L. Clinical evaluation of the GSD NovaPrime® SARS-CoV-2 RTq-PCR assay. Diagn Microbiol Infect Dis 2022; 103:115718. [PMID: 35641362 PMCID: PMC9061580 DOI: 10.1016/j.diagmicrobio.2022.115718] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Revised: 04/24/2022] [Accepted: 04/26/2022] [Indexed: 11/03/2022]
|
8
|
Tré-Hardy M, Cupaiolo R, Wilmet A, Antoine-Moussiaux T, Coman-Viagea N, Vecchia AD, Horeanga A, Papleux E, Vekemans M, Beukinga I, Blairon L. Assessment 2 months after the administration of a 3rd dose mRNA: A new variant-adapted vaccine is expected. J Infect 2022; 84:e31-e33. [PMID: 35181372 PMCID: PMC8847092 DOI: 10.1016/j.jinf.2022.02.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2022] [Accepted: 02/11/2022] [Indexed: 10/25/2022]
Affiliation(s)
- Marie Tré-Hardy
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium.; Faculty of Medicine, Université libre de Bruxelles, Brussels, Belgium; epartment of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Belgium..
| | - Roberto Cupaiolo
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Alain Wilmet
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | | | | | | | - Alexandra Horeanga
- Department of Infectious Diseases, Iris Hospitals South, Brussels, Belgium
| | | | - Marc Vekemans
- Department of Infectious Diseases, Iris Hospitals South, Brussels, Belgium
| | - Ingrid Beukinga
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Laurent Blairon
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| |
Collapse
|
9
|
Tré-Hardy M, Cupaiolo R, Wilmet A, Antoine-Moussiaux T, Della Vecchia A, Horeanga A, Papleux E, Vekemans M, Beukinga I, Blairon L. Six-month interim analysis of ongoing immunogenicity surveillance of the mRNA-1273 vaccine in healthcare workers: A third dose is expected. J Infect 2021; 83:559-564. [PMID: 34437927 PMCID: PMC8380546 DOI: 10.1016/j.jinf.2021.08.031] [Citation(s) in RCA: 48] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Accepted: 08/18/2021] [Indexed: 01/06/2023]
Abstract
Objectives Scarce data are currently available on the kinetics of antibodies after vaccination with mRNA vaccines as a whole and, with mRNA-1273, in particular. We report here an ad-interim analysis of data obtained after a 6-month follow-up in a cohort of healthcare workers (HCWs) who received the mRNA-1273 vaccine. These new data provide more insight into whether and in whom a 3rd dose could be necessary. Methods Our study compared the anti-S antibody kinetics at 2 weeks (T1), 3 months (T3) and 6 months (T4) after the first injection, and 2 weeks after the second injection (T2). The 201 participating HCWs were stratified according to their initial serological status. The vaccine effectiveness was also assessed through a medical questionnaire. Results We report here a marked and statistically significant antibody decrease (P < 0.05) between T3 and T4, especially in naïve vaccinees. The analysis of potential confounding factors or known risk factors for severe COVID-19 disease did not reveal any influence on the drop observed. Six-month after vaccination, only one, symptomatic, infection was reported in our cohort. Conclusions In a supply-limited environment, our results plead for reserving the 3rd dose scheme, in the upcoming months, to seronegative individuals prior to vaccination, especially when the serological status is easily accessible.
Collapse
Affiliation(s)
- Marie Tré-Hardy
- Department of Laboratory Medicine, Iris Hospitals South, rue Jean Paquot 63, 1050 Brussels, Brussels, Belgium; Faculty of Medicine, Université libre de Bruxelles, Brussels, Belgium; Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Belgium.
| | - Roberto Cupaiolo
- Department of Laboratory Medicine, Iris Hospitals South, rue Jean Paquot 63, 1050 Brussels, Brussels, Belgium
| | - Alain Wilmet
- Department of Laboratory Medicine, Iris Hospitals South, rue Jean Paquot 63, 1050 Brussels, Brussels, Belgium
| | | | | | - Alexandra Horeanga
- Department of Infectious Diseases, Iris Hospitals South, Brussels, Belgium
| | | | - Marc Vekemans
- Department of Infectious Diseases, Iris Hospitals South, Brussels, Belgium
| | - Ingrid Beukinga
- Department of Laboratory Medicine, Iris Hospitals South, rue Jean Paquot 63, 1050 Brussels, Brussels, Belgium
| | - Laurent Blairon
- Department of Laboratory Medicine, Iris Hospitals South, rue Jean Paquot 63, 1050 Brussels, Brussels, Belgium
| |
Collapse
|
10
|
Blairon L, Cupaiolo R, Piteüs S, Beukinga I, Tré-Hardy M. The challenge of screening SARS-CoV-2 variants of concern with RT-qPCR: One variant can hide another. J Virol Methods 2021; 297:114248. [PMID: 34332998 PMCID: PMC8320429 DOI: 10.1016/j.jviromet.2021.114248] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2021] [Revised: 07/27/2021] [Accepted: 07/27/2021] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Following the emergence of SARS-CoV-2 variants of concern (VOCs) worldwide, it is important to monitor local epidemiology to better understand the occurrence of clusters, reinfections, or infection after vaccination. Detecting mutations by specific RT-qPCR is a rapid and affordable alternative to sequencing. However, care must be taken to ensure that the techniques used are up-to-date and adapted to the variants circulating in the studied population. MATERIAL AND METHODS All samples tested positive for SARS-CoV-2 were screened for detection of mutations of the spike protein using the Novaplex™ SARS-CoV-2 Variants I Assay from week 11 of 2021. Target sought were deletion H69/V70 and mutations N501Y and E484 K. From week 18 we used in addition the new Novaplex™ SARS-CoV-2 Variants II Assay for samples with no targets found with the Variants I assay or with the mutation E484 K alone, in order to screen the mutations L452R, K417 N/T and W152C. RESULTS Between weeks 11 and 25, 2239 positive samples out of 54,317 were tested with the Variants I Assay. Between weeks 18 and 25, 94 samples met the criteria for being tested with the Variants II Assay. Of these, 47 had the L452R mutation without the W152C mutation, typical in the B.1.617 variant. At week 25, this profile was found in 45.5 % of the samples and was the most frequent. CONCLUSION According to our observations, variant B.1.617 has become predominant in our institution and most probably in our region. In the absence of the use of the Variants II Assay, they would have been considered wild.
Collapse
Affiliation(s)
- Laurent Blairon
- Laboratory Medicine, Iris Hospitals South, 63 rue Jean Paquot, 1050 Brussels, Belgium.
| | - Roberto Cupaiolo
- Laboratory Medicine, Iris Hospitals South, 63 rue Jean Paquot, 1050 Brussels, Belgium
| | - Sébastien Piteüs
- Laboratory Medicine, Iris Hospitals South, 63 rue Jean Paquot, 1050 Brussels, Belgium
| | - Ingrid Beukinga
- Laboratory Medicine, Iris Hospitals South, 63 rue Jean Paquot, 1050 Brussels, Belgium
| | - Marie Tré-Hardy
- Laboratory Medicine, Iris Hospitals South, 63 rue Jean Paquot, 1050 Brussels, Belgium; Faculty of Medicine, Université libre de bruxelles, Brussels, Belgium; Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Belgium
| |
Collapse
|
11
|
Tré-Hardy M, Cupaiolo R, Wilmet A, Beukinga I, Blairon L. Waning antibodies in SARS-CoV-2 naïve vaccinees: Results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers. J Infect 2021; 83:381-412. [PMID: 34161817 PMCID: PMC8214908 DOI: 10.1016/j.jinf.2021.06.017] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2021] [Accepted: 06/17/2021] [Indexed: 11/29/2022]
Affiliation(s)
- Marie Tré-Hardy
- Department of Laboratory Medicine, Iris Hospitals South, rue Jean Paquot 63, Brussels 1050, Belgium; Faculty of Medicine, Université libre de bruxelles, Brussels, Belgium; Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Belgium.
| | - Roberto Cupaiolo
- Department of Laboratory Medicine, Iris Hospitals South, rue Jean Paquot 63, Brussels 1050, Belgium
| | - Alain Wilmet
- Department of Laboratory Medicine, Iris Hospitals South, rue Jean Paquot 63, Brussels 1050, Belgium
| | - Ingrid Beukinga
- Department of Laboratory Medicine, Iris Hospitals South, rue Jean Paquot 63, Brussels 1050, Belgium
| | - Laurent Blairon
- Department of Laboratory Medicine, Iris Hospitals South, rue Jean Paquot 63, Brussels 1050, Belgium
| |
Collapse
|
12
|
Blairon L, Cupaiolo R, Thomas I, Piteüs S, Wilmet A, Beukinga I, Tré-Hardy M. Efficacy comparison of three rapid antigen tests for SARS-CoV-2 and how viral load impact their performance. J Med Virol 2021; 93:5783-5788. [PMID: 34050945 PMCID: PMC8242364 DOI: 10.1002/jmv.27108] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2021] [Revised: 04/27/2021] [Accepted: 05/26/2021] [Indexed: 12/15/2022]
Abstract
More and more rapid antigen tests for the diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appear in the market with varying performance. The sensitivity of these tests heavily depends on the viral load, extrapolated by the threshold cycle (Ct). It is therefore essential to verify their performance before their inclusion in routine. The Coronavirus Ag Rapid Test Cassette Bio-Rad, the GSD NovaGen SARS-CoV-2 (COVID-19) Antigen Rapid Test, and the Aegle Coronavirus Ag Rapid Test Cassette were evaluated on 199 samples: 150 fresh samples from the routine and positive in quantitative reverse-transcription polymerase chain reaction (RT-qPCR), nine fresh samples negative in RT-qPCR, and 40 frozen samples, taken before the discovery of SARS-CoV-2 but positive for other respiratory viruses. Positive RT-qPCR samples were categorized according to their Ct: Ct < 20 (18.7%), ≥ 20-< 25 (27.3%), ≥ 25-< 30 (18.7%), ≥ 30-35 (17.3%), and > 35 (18.0%). Sensitivities (95% confidence interval) for Ct below 25 were 95.7% (92.4-98.9), 97.1% (94.4-99.8), and 97.1% (94.4-99.8) for GSD NovaGen, Bio-Rad, and Aegle, respectively but drastically dropped when Ct exceeded 27. Among samples with previously diagnosed viruses, seven false-positive results were found with GSD NovaGen only (specificity 85.7%). Equivalent, high sensitivities were observed with the highest viral load samples. The GSD NovaGen assay showed less specificity. Although the three kits tested in this study are inadequate for routine testing in a high throughput laboratory, they can help to quickly identify the most infectious patients and screen their close contacts in an environment where molecular tests are not readily available.
Collapse
Affiliation(s)
- Laurent Blairon
- Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | | | | | | | - Alain Wilmet
- Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Ingrid Beukinga
- Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Marie Tré-Hardy
- Laboratory Medicine, Iris Hospitals South, Brussels, Belgium.,Faculty of Medicine, Université libre de Bruxelles, Brussels, Belgium.,Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Namur, Belgium
| |
Collapse
|
13
|
Tré-Hardy M, Cupaiolo R, Papleux E, Wilmet A, Horeanga A, Antoine-Moussiaux T, Della Vecchia A, Beukinga I, Vekemans M, Blairon L. Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers. J Infect 2021; 83:237-279. [PMID: 33811939 PMCID: PMC8012163 DOI: 10.1016/j.jinf.2021.03.025] [Citation(s) in RCA: 43] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 03/27/2021] [Accepted: 03/30/2021] [Indexed: 01/19/2023]
Affiliation(s)
- Marie Tré-Hardy
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium; Faculty of Medicine, Université libre de bruxelles, Brussels, Belgium; Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Belgium.
| | - Roberto Cupaiolo
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | | | - Alain Wilmet
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Alexandra Horeanga
- Department of Infectious Diseases, Iris Hospitals South, Brussels, Belgium
| | | | | | - Ingrid Beukinga
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Marc Vekemans
- Department of Infectious Diseases, Iris Hospitals South, Brussels, Belgium
| | - Laurent Blairon
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| |
Collapse
|
14
|
Haguet H, Douxfils J, Eucher C, Elsen M, Cadrobbi J, Tré-Hardy M, Dogné JM, Favresse J. Clinical performance of the Panbio assay for the detection of SARS-CoV-2 IgM and IgG in COVID-19 patients. J Med Virol 2021; 93:3277-3281. [PMID: 33599299 PMCID: PMC8014867 DOI: 10.1002/jmv.26884] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Revised: 02/03/2021] [Accepted: 02/15/2021] [Indexed: 02/02/2023]
Abstract
Following the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic, numerous serological tests have been developed, including rapid diagnostic tests. This study aims at assessing the clinical performance of the Panbio immunoglobulin G (IgG)/IgM coronavirus disease 2019 (COVID‐19) test (Abbott), a rapid lateral flow assay for the qualitative detection of IgG and IgM against SARS‐CoV‐2. One hundred and thirty‐eight samples from 95 COVID‐19 patients with a positive SARS‐CoV‐2 reverse‐transcriptase polymerase chain reaction were analyzed to assess the clinical sensitivity. Seventy‐six pre‐COVID‐19 samples were used to evaluate the clinical specificity. Two independent and blinded raters determined visually the presence or absence of the IgG, IgM, and control lines for each test after 10 and 20 min. The sensitivity obtained from collected samples more than 14 days after the onset of symptoms was 95.2% for IgG. IgM was less frequently detected (highest sensitivity of 20.5%). The specificities obtained were 98.7% and 100% for IgG and IgM, respectively. In addition, the sensitivity of the assay was better when the reading was performed at 20 min than at 10 min, whereas the specificity was unchanged. The Panbio COVID‐19 IgG/IgM rapid test detects IgG with high sensitivity 14 days since symptom onset but presents a low sensitivity for IgM. The specificity was excellent for both IgG and IgM. ‐ The Panbio IgG/IgM COVID‐19 test (Abbott) is a rapid lateral flow assay for the qualitative detection of IgG and IgM. ‐ It detects IgG with high sensitivity 14 days since symptom onset (95.2%) but presents a low sensitivity for IgM. ‐ The sensitivity of the assay is better when the reading is performed at 20 min than at 10 min.
Collapse
Affiliation(s)
- Hélène Haguet
- Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium
| | - Jonathan Douxfils
- Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium.,Qualiblood sa, Namur, Belgium
| | - Christine Eucher
- Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium
| | - Marc Elsen
- Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium
| | - Julie Cadrobbi
- Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium
| | - Marie Tré-Hardy
- Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium.,Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium.,Faculty of Medicine, Université libre de Bruxelles, Brussels, Belgium
| | - Jean-Michel Dogné
- Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium
| | - Julien Favresse
- Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium.,Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium
| |
Collapse
|
15
|
Blairon L, Thomas I, Lê PQ, Beukinga I, Tré-Hardy M. Diagnosis of respiratory syncytial virus and influenza A and B with cobas® Liat® from nasopharyngeal aspirations in pediatrics. Diagn Microbiol Infect Dis 2021; 100:115326. [PMID: 33581424 DOI: 10.1016/j.diagmicrobio.2021.115326] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Revised: 01/05/2021] [Accepted: 01/24/2021] [Indexed: 10/22/2022]
Abstract
The cobas® Liat® Influenza A/B and respiratory syncytial virus assay was tested on nasopharyngeal aspirates. The resolution of invalid samples was performed using a preanalytical step. cobas® Liat® can be used on nasopharyngeal aspirates with a preanalytical processing step, with a slightly diminished performances in detecting respiratory syncytial virus but not for influenza.
Collapse
Affiliation(s)
- Laurent Blairon
- Laboratory Medicine, Iris Hospitals South, Brussels, Belgium.
| | | | - Phu-Quoc Lê
- Department of Pediatrics, Iris Hospitals South, Brussels, Belgium
| | - Ingrid Beukinga
- Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Marie Tré-Hardy
- Laboratory Medicine, Iris Hospitals South, Brussels, Belgium; Faculty of Medicine, Université libre de bruxelles, Brussels, Belgium; Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Namur, Belgium
| |
Collapse
|
16
|
Blairon L, Piteüs S, Beukinga I, Tré-Hardy M. Development and implementation of a RT-qPCR extraction-free protocol for the detection of SARS-CoV-2 and impact on the turn-around-time. J Med Virol 2021; 93:2538-2542. [PMID: 33415765 DOI: 10.1002/jmv.26782] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Revised: 01/04/2021] [Accepted: 01/05/2021] [Indexed: 12/20/2022]
Abstract
The occurrence of the COVID-19 second-wave outbreak in Europe has pushed laboratories performing molecular SARS-CoV-2 tests to increase their throughput and decrease the result rendering time. In this evaluation, we tested for the first time a new, extraction-free, protocol with the Allplex SARS-CoV-2 Assay RT-qPCR kit on a Nimbus platform. Ninety-one samples, of which 71 previously tested positive with RT-qPCR with extraction were immediately analyzed without extraction, using only a dilution and thermal shock protocol. The positive and negative percentage agreements were respectively 97.2% (95% confidence interval [CI]: 0.90-0.99) and 95.0% (95% CI: 0.76-0.99). The two false negatives observed were very weakly positive with the comparison method. Moderate variations in Ct of the targeted genes were observed (median ± 95% CI): E gene, +2.49 ± 0.44; N gene, +0.98 ± 0.54; RdRP/S genes, +2.64 ± 0.48. On the other hand, the number of tests performed within 24 h raised from 86.4% to 97.8%, the turn-around time decreased from 19:18 to 09:03 (p < .0001), and the number of tests that can be performed per day doubled since this technique was introduced routinely in our laboratory.
Collapse
Affiliation(s)
- Laurent Blairon
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Sébastien Piteüs
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Ingrid Beukinga
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Marie Tré-Hardy
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium.,Faculty of Medicine, Université libre de Bruxelles, Brussels, Belgium.,Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Namur, Belgium
| |
Collapse
|
17
|
Mairesse A, Favresse J, Eucher C, Elsen M, Tré-Hardy M, Haventith C, Gruson D, Dogné JM, Douxfils J, Göbbels P. High clinical performance and quantitative assessment of antibody kinetics using a dual recognition assay for the detection of SARS-CoV-2 IgM and IgG antibodies. Clin Biochem 2020; 86:23-27. [PMID: 32858061 PMCID: PMC7445483 DOI: 10.1016/j.clinbiochem.2020.08.009] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2020] [Revised: 08/11/2020] [Accepted: 08/19/2020] [Indexed: 01/08/2023]
Abstract
OBJECTIVES Several serological SARS-CoV-2 immunoassays have been developed recently but require external validation before widespread use. This study aims at assessing the analytical and clinical performance of the iFlash® anti-SARS-CoV-2 chemiluminescence assay for the detection of both IgM and IgG antibodies. The kinetics of the antibody response was also evaluated. DESIGN & METHODS The precision, carry-over, linearity, limit of blank, detection and quantification were assessed. Sensitivity analysis was performed by using 178 sera collected from 154 RT-PCR confirmed COVID-19 patients. The specificity analysis was performed from 75 selected non-SARS-CoV-2 sera with a potential cross-reaction to the SARS-CoV-2 immunoassay. RESULTS This iFlash® SARS-CoV-2 assay showed excellent analytical performance. After 2 weeks since symptom onset, the sensitivities for IgM and IgG were 62.2% (95% CI: 52.3-71.2%) and 92.9%% (95% CI: 85.7-96.7%), respectively by using the cut-off provided by the manufacturer. After cut-off optimization (i.e. >2.81 for IgM and >4.86 for IgG), the sensitivity for IgM and IgG were 81.6 (95% CI: 72.7-88.1%) and 95.9% (95% CI: 89.4-98.7%), respectively. Optimized cut-off for IgG improved the sensitivity to reach 100% (95%CI: 87.6-100) from 28 days since symptom onset. CONCLUSIONS This study shows that the iFlash® SARS-CoV-2 assay from YHLO biotechnology, has satisfactory analytical performance. Nevertheless, the sensitivity of the IgM is limited for a proper clinical use compared to IgG. The determination of anti-SARS-CoV-2 IgG antibodies from 28 days since symptom onset was associated with high sensitivity, especially using optimized cut-offs (i.e. 100%).
Collapse
Affiliation(s)
- Antoine Mairesse
- Department of Laboratory Medicine, Cliniques Universitaires St-Luc and Université catholique de Louvain, Brussels, Belgium
| | - Julien Favresse
- Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium; Department of Pharmacy, Namur Research Institute for LIfes Sciences, University of Namur, Belgium
| | - Christine Eucher
- Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium
| | - Marc Elsen
- Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium
| | - Marie Tré-Hardy
- Department of Pharmacy, Namur Research Institute for LIfes Sciences, University of Namur, Belgium; Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium; Faculty of Medicine, Université libre de Bruxelles, Brussels, Belgium
| | - Caroline Haventith
- Department of Laboratory Medicine, Saint Nikolaus Hospital, Eupen, Belgium
| | - Damien Gruson
- Department of Laboratory Medicine, Cliniques Universitaires St-Luc and Université catholique de Louvain, Brussels, Belgium
| | - Jean-Michel Dogné
- Department of Pharmacy, Namur Research Institute for LIfes Sciences, University of Namur, Belgium
| | - Jonathan Douxfils
- Department of Pharmacy, Namur Research Institute for LIfes Sciences, University of Namur, Belgium; Qualiblood sa, Namur, Belgium.
| | - Paul Göbbels
- Department of Laboratory Medicine, Saint Nikolaus Hospital, Eupen, Belgium
| |
Collapse
|
18
|
Gillot C, Douxfils J, Cadrobbi J, Laffineur K, Dogné JM, Elsen M, Eucher C, Melchionda S, Modaffarri É, Tré-Hardy M, Favresse J. An Original ELISA-Based Multiplex Method for the Simultaneous Detection of 5 SARS-CoV-2 IgG Antibodies Directed against Different Antigens. J Clin Med 2020; 9:E3752. [PMID: 33233405 PMCID: PMC7700260 DOI: 10.3390/jcm9113752] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2020] [Revised: 11/17/2020] [Accepted: 11/19/2020] [Indexed: 12/22/2022] Open
Abstract
Strategies to detect SARS-CoV-2 are increasingly being developed. Among them, serological methods have been developed. Nevertheless, although these may present an interesting clinical performance, they are often directed against only one antigen. This study aims at evaluating the clinical performance of an innovative multiplex immunoassay (i.e., CoViDiag assay) detecting simultaneously the presence of antibodies directed against N, S1, S2, RBD and NTD antigens. Sensitivity was evaluated in 135 samples obtained from 94 rRT-PCR confirmed coronavirus disease 2019 (COVID-19) patients. Non-SARS-CoV-2 sera (n = 132) collected before the COVID-19 pandemic with potential cross-reactions to the SARS-CoV-2 immunoassay were included in the specificity analysis. The antibody signature was also studied in hospitalized and non-hospitalized patients. The specificity of the CoViDiag assay was excellent for all antibodies (99.2 to 100%) using adapted cut-offs. None of the false positive samples were positive for more than one antibody. The sensitivity obtained from samples collected 14 days since symptom onset varied from 92.0 to 100.0% depending on the antibody considered. Among samples collected more than 14 days after symptom onset, 12.8, 66.3, 3.5, 9.3, 5.8 and 2.3% were positive for 5, 4, 3, 2, 1 or 0 antibodies, respectively. A trend toward higher antibody titers was observed in hospitalized patient in the early days since symptom onset. However, no significant difference was observed compared to non-hospitalized patients after 14 days since symptom onset. The clinical performance of the CoViDiag 5 IgG assay is sufficient to recommend its use for the detection and the characterization of the antibody signature following SARS-CoV-2 infection. The combination of several antigens in the same test improves the overall specificity and sensitivity of the test. Further research is needed to investigate whether this strategy may be of interest to identify severe disease outcome in patients with SARS-CoV-2 infection.
Collapse
Affiliation(s)
- Constant Gillot
- Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, B-5000 Namur, Belgium; (C.G.); (J.-M.D.); (M.T.-H.); (J.F.)
| | - Jonathan Douxfils
- Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, B-5000 Namur, Belgium; (C.G.); (J.-M.D.); (M.T.-H.); (J.F.)
- Central Laboratory Department, Qualiblood sa, 5000 Namur, Belgium; (S.M.); (É.M.)
| | - Julie Cadrobbi
- Department of Laboratory Medicine, Clinique St-Luc Bouge, 5004 Namur, Belgium; (J.C.); (K.L.); (M.E.); (C.E.)
| | - Kim Laffineur
- Department of Laboratory Medicine, Clinique St-Luc Bouge, 5004 Namur, Belgium; (J.C.); (K.L.); (M.E.); (C.E.)
| | - Jean-Michel Dogné
- Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, B-5000 Namur, Belgium; (C.G.); (J.-M.D.); (M.T.-H.); (J.F.)
| | - Marc Elsen
- Department of Laboratory Medicine, Clinique St-Luc Bouge, 5004 Namur, Belgium; (J.C.); (K.L.); (M.E.); (C.E.)
| | - Christine Eucher
- Department of Laboratory Medicine, Clinique St-Luc Bouge, 5004 Namur, Belgium; (J.C.); (K.L.); (M.E.); (C.E.)
| | - Sabrina Melchionda
- Central Laboratory Department, Qualiblood sa, 5000 Namur, Belgium; (S.M.); (É.M.)
| | - Élise Modaffarri
- Central Laboratory Department, Qualiblood sa, 5000 Namur, Belgium; (S.M.); (É.M.)
| | - Marie Tré-Hardy
- Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, B-5000 Namur, Belgium; (C.G.); (J.-M.D.); (M.T.-H.); (J.F.)
- Department of Laboratory Medicine, Iris Hospitals South, 1060 Brussels, Belgium
- Faculty of Medicine, Université libre de Bruxelles, 1050 Brussels, Belgium
| | - Julien Favresse
- Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, B-5000 Namur, Belgium; (C.G.); (J.-M.D.); (M.T.-H.); (J.F.)
- Department of Laboratory Medicine, Clinique St-Luc Bouge, 5004 Namur, Belgium; (J.C.); (K.L.); (M.E.); (C.E.)
| |
Collapse
|
19
|
Favresse J, Eucher C, Elsen M, Tré-Hardy M, Dogné JM, Douxfils J. Clinical Performance of the Elecsys Electrochemiluminescent Immunoassay for the Detection of SARS-CoV-2 Total Antibodies. Clin Chem 2020; 66:1104-1106. [PMID: 32484887 PMCID: PMC7314109 DOI: 10.1093/clinchem/hvaa131] [Citation(s) in RCA: 85] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/30/2020] [Indexed: 12/28/2022]
Affiliation(s)
- Julien Favresse
- Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium.,Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Belgium
| | - Christine Eucher
- Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium
| | - Marc Elsen
- Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium
| | - Marie Tré-Hardy
- Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Belgium.,Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium.,Faculty of Medicine, Université libre de Bruxelles, Brussels, Belgium
| | - Jean-Michel Dogné
- Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Belgium
| | - Jonathan Douxfils
- Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Belgium.,Qualiblood sa, Namur, Belgium
| |
Collapse
|
20
|
Tré-Hardy M, Blairon L, Wilmet A, Beukinga I, Malonne H, Dogné JM, Douxfils J. The role of serology for COVID-19 control: Population, kinetics and test performance do matter. J Infect 2020; 81:e91-e92. [PMID: 32417311 PMCID: PMC7228733 DOI: 10.1016/j.jinf.2020.05.019] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Accepted: 05/09/2020] [Indexed: 10/25/2022]
Affiliation(s)
- Marie Tré-Hardy
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium; Faculty of Medicine, Université libre de Bruxelles, Brussels, Belgium; Department of Pharmacy, NAmur Research Institute for LIfes Sciences, University of Namur, Belgium
| | - Laurent Blairon
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Alain Wilmet
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Ingrid Beukinga
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Hugues Malonne
- Federal Agency for Medicines and Healthcare Products, Brussels, Belgium; Unit of Pharmacology, Pharmacotherapy and Pharmaceutical care, Faculty of Pharmacy, Université libre de Bruxelles, Brussels, Belgium; Department of Biomedical Sciences, NAmur Research Institute for Lifes Sciences, University of Namur, Belgium
| | - Jean-Michel Dogné
- Department of Pharmacy, NAmur Research Institute for LIfes Sciences, University of Namur, Belgium
| | - Jonathan Douxfils
- Department of Pharmacy, NAmur Research Institute for LIfes Sciences, University of Namur, Belgium; Qualiblood sa, Namur, Belgium.
| |
Collapse
|
21
|
Blairon L, Mokrane S, Wilmet A, Dessilly G, Kabamba-Mukadi B, Beukinga I, Tré-Hardy M. Large-scale, molecular and serological SARS-CoV-2 screening of healthcare workers in a 4-site public hospital in Belgium after COVID-19 outbreak. J Infect 2020; 82:159-198. [PMID: 32739485 PMCID: PMC7392848 DOI: 10.1016/j.jinf.2020.07.033] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2020] [Accepted: 07/28/2020] [Indexed: 12/25/2022]
Affiliation(s)
- Laurent Blairon
- Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Saphia Mokrane
- Infection Control, Iris Hospitals South, Brussels, Belgium
| | - Alain Wilmet
- Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Géraldine Dessilly
- Université Catholique de Louvain, Institute of Experimental and Clinical Research, Microbiology, Brussels, Belgium; St-Luc University Hospital, Brussels, Belgium
| | - Benoît Kabamba-Mukadi
- Université Catholique de Louvain, Institute of Experimental and Clinical Research, Microbiology, Brussels, Belgium; St-Luc University Hospital, Brussels, Belgium
| | - Ingrid Beukinga
- Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Marie Tré-Hardy
- Laboratory Medicine, Iris Hospitals South, Brussels, Belgium; Faculty of Medicine, Université libre de Bruxelles, Brussels, Belgium; Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Belgium.
| |
Collapse
|
22
|
Tré-Hardy M, Wilmet A, Beukinga I, Favresse J, Dogné JM, Douxfils J, Blairon L. Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies. J Med Virol 2020; 93:803-811. [PMID: 32667733 PMCID: PMC7405491 DOI: 10.1002/jmv.26303] [Citation(s) in RCA: 66] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2020] [Revised: 07/09/2020] [Accepted: 07/11/2020] [Indexed: 01/03/2023]
Abstract
The development of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) serological tests is massive. The external validation of their performance is needed before use in clinical routine practice. Our study aims at assessing the analytical and clinical performance of two enzyme‐linked immunosorbent assay tests detecting antibodies directed against the virus nucleocapsid protein: The NovaLisa SARS‐CoV‐2 immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) test (NovaTec) allowing a separate detection of each antibody and the Platelia SARS‐CoV‐2 Total Ab test (Bio‐Rad) detecting total antibodies (IgM, IgA, and IgG). Two‐hundred and eight coronavirus disease 2019 samples from 48 quantitative reverse transcription‐polymerase chain reaction (RT‐qPCR) confirmed patients were used to perform the sensitivity analysis. Non‐SARS‐CoV‐2 sera (n = 79) with a potential cross‐reaction to SARS‐CoV‐2 immunoassays were included in the specificity analysis. In addition, using receiver operator characteristic curves, adapted cut‐off for improvement of the performances were proposed. The kinetics of these antibodies was also assessed over 8 weeks. Two weeks after the RT‐qPCR positive detection, the NovaLisa test shows a sensitivity and specificity of 94.9% (95% confidence interval [CI]: 83.1%‐98.6%) and 96.2% (95% CI: 89.4%‐98.7%) for IgG, of 89.7% (95% CI: 76.4%‐95.9%) and 98.7% (95% CI: 93.2%‐98.8%) for IgA, and of 48.7% (95% CI: 33.9%‐63.8%) and 98.7% (95% CI: 93.2%‐99.8%) for IgM. With the Platelia system, the specificity and sensitivity were 97.4% (95% CI: 92.1%‐99.7%) and 94.9% (95% CI: 87.7%‐98.0%) for total antibodies using the adapted cut‐offs. The NovaLisa and the Platelia tests have satisfactory analytical performances. The clinical performances are excellent for IgG, IgA, and total antibodies especially if the cut‐off is optimized. The sensitivity and the specificity of the NovaLisa (for immunoglobulin G [IgG] and immunoglobulin A [IgA]) and the Platelia were excellent. Cut‐off optimizations improve the clinical performances of both assays. Over a period of 8 weeks, IgM and IgA gradually disappeared while IgG remain persistent.
Collapse
Affiliation(s)
- Marie Tré-Hardy
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium.,Faculty of Medicine, Université libre de Bruxelles, Brussels, Belgium.,Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium
| | - Alain Wilmet
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Ingrid Beukinga
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Julien Favresse
- Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium
| | - Jean-Michel Dogné
- Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium
| | - Jonathan Douxfils
- Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium.,Qualiblood sa, Namur, Belgium
| | - Laurent Blairon
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| |
Collapse
|
23
|
Blairon L, Wilmet A, Beukinga I, Tré-Hardy M. Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: Experiences of a general hospital. J Clin Virol 2020; 129:104472. [PMID: 32504944 PMCID: PMC7261076 DOI: 10.1016/j.jcv.2020.104472] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2020] [Revised: 05/22/2020] [Accepted: 05/25/2020] [Indexed: 01/16/2023]
Abstract
The COVID-19 Ag Respi-Strip assay is a new immunochromatographic diagnostic tool for antigenic diagnosis of SARS-CoV-2. This test did not reduce significantly the number of samples outsourced for COVID-19 confirmation. The sensitivity of this rapid test is poor and improvements are needed to enhance its performances.
Background The COVID-19 Ag (Antigen) Respi-Strip assay is a new immunochromatographic diagnostic tool recently available for antigenic diagnosis of SARS-CoV-2. The proposed sensitivity is not higher than 60 %, but its high specificity allows both quick decisions for the management of patients and confirmation by molecular diagnosis for only negative tests. However, from the first tests performed, we suspected that the sensitivity observed with routine use was much lower than that announced by the manufacturer. Materials and methods Over a period of one month, we compared the negative results obtained with the COVID-19 Ag Respi-Strip kit with those obtained from qRT-PCR performed in a laboratory qualified for the molecular diagnosis of SARS-CoV-2. All samples tested were naso-pharyngeal smears from UTM-RT medium. Results Of 774 patients tested, 714 negative samples were sent for confirmation, and 159 were found to be positive by qRT-PCR. The median positive percentage agreement was 23.9 % (95 % CI: 14.2 %–38.2 %). The Cohen’s kappa score was 0.35. Conclusion Using this immunochromatographic assay as a triage test did not significantly reduce the number of samples outsourced for COVID-19 confirmation by qRT-PCR. In addition, even if the turn-around time is short, the assay is completely manual, which is not suitable for large volumes of routine samples. The sensitivity of this rapid test is poor, and improvements are needed to enhance its performance.
Collapse
Affiliation(s)
- Laurent Blairon
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Alain Wilmet
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Ingrid Beukinga
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
| | - Marie Tré-Hardy
- Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium; Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Belgium; Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium.
| |
Collapse
|
24
|
Tré-Hardy M, Wilmet A, Beukinga I, Dogné JM, Douxfils J, Blairon L. Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody. ACTA ACUST UNITED AC 2020; 58:1357-1364. [DOI: 10.1515/cclm-2020-0594] [Citation(s) in RCA: 67] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2020] [Accepted: 05/09/2020] [Indexed: 12/30/2022]
Abstract
Abstract
Objectives
Faced with the COVID-19 pandemic and its impact on the availability and quality of both therapeutic and diagnostic methods, the Belgian authorities have decided to launch a procedure for additional evaluation of the performance of serological tests offered for sale on the national territory. This has been proposed with a double aim: (1) an in-depth verification of the analytical and clinical performances presented by the manufacturer and (2) an economy of scale in terms of centralized validation for all the laboratories using the tests subject to evaluation.
Methods
A retrospective validation study was conducted including the serum of 125 patients in order to determine the analytical and clinical performances of the LIAISON®SARS-CoV-2 from DiaSorin® detecting anti-SARS-CoV-2 IgG and to compare its clinical performance with the enzyme-linked immunosorbent assay (ELISA) test from Euroimmun®, one of the first commercially available tests allowing the detection of anti-SARS-CoV-2 IgA and IgG.
Results
The performances of the LIAISON®SARS-CoV-2 satisfied all the acceptance criteria and provided “real world” analytical and clinical performances very close to the ones reported by the manufacturer in its insert kit. Comparison between the LIAISON®SARS-CoV-2 and the ELISA method did not reveal any difference between the two techniques in terms of sensitivities and specificities regarding the determination of the IgG.
Conclusions
This study reports the validation of the LIAISON®SARS-CoV-2 allowing to detect IgG antibodies specifically directed against SARS-CoV-2. The analytical and clinical performances are excellent, and the automation of the test offers important rates, ideal for absorbing an extension of testing.
Collapse
Affiliation(s)
- Marie Tré-Hardy
- Department of Laboratory Medicine , Iris Hospitals South , rue Jean Paquot 63 , 1050 Brussels , Belgium
- Faculty of Medicine , Université libre de Bruxelles , Brussels , Belgium
- Department of Pharmacy , Namur Research Institute for Life Sciences, University of Namur , Namur , Belgium , Phone: +32 2 641 48 21, Fax: + 32 2 641 48 24
| | - Alain Wilmet
- Department of Laboratory Medicine , Iris Hospitals South , Brussels , Belgium
| | - Ingrid Beukinga
- Department of Laboratory Medicine , Iris Hospitals South , Brussels , Belgium
| | - Jean-Michel Dogné
- Department of Pharmacy , Namur Research Institute for Life Sciences, University of Namur , Namur , Belgium
| | - Jonathan Douxfils
- Department of Pharmacy , Namur Research Institute for Life Sciences, University of Namur , Namur , Belgium
- Qualiblood sa , Namur , Belgium
| | - Laurent Blairon
- Department of Laboratory Medicine , Iris Hospitals South , Brussels , Belgium
| |
Collapse
|
25
|
Tré-Hardy M, Lambert B, Despas N, Bressant F, Laurenzano C, Rodriguez-Villalobos H, Verroken A. MALDI-TOF MS identification and antimicrobial susceptibility testing directly from positive enrichment broth. J Microbiol Methods 2017; 141:32-34. [PMID: 28754447 DOI: 10.1016/j.mimet.2017.07.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2017] [Revised: 07/24/2017] [Accepted: 07/24/2017] [Indexed: 11/18/2022]
Abstract
A rapid preparation procedure was validated for MALDI-TOF MS identification followed by an antimicrobial susceptibility testing directly from a non-selective enrichment broth of sterile fluid samples associated with negative classical cultures. This method can be easily integrated in the laboratory routine allowing precious time gain for microbe identification and subsequent adequate treatment initiation.
Collapse
Affiliation(s)
- Marie Tré-Hardy
- Department of Microbiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
| | - Barbara Lambert
- Department of Microbiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Noémie Despas
- Department of Microbiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Florian Bressant
- Department of Microbiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Clémentine Laurenzano
- Department of Microbiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Hector Rodriguez-Villalobos
- Department of Microbiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Alexia Verroken
- Department of Microbiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| |
Collapse
|
26
|
Tré-Hardy M, Le Goff C, Gruson D. Testing of total 25(OH)vitamin D: agreement and discrepant cases between Cobas® 8000 and Liaison® XL methods. Clin Chem Lab Med 2017; 54:e391-e394. [PMID: 27176744 DOI: 10.1515/cclm-2016-0176] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2016] [Accepted: 03/28/2016] [Indexed: 11/15/2022]
|
27
|
Mertes H, Defourny L, Tré-Hardy M, Lhommel R, El Khoury G, Rodriguez-Villalobos H, Belkhir L. First Robinsoniella peoriensis aortic cross homograft mycotic pseudoaneurysm: A case report and review of the literature. Anaerobe 2016; 44:23-26. [PMID: 28043924 DOI: 10.1016/j.anaerobe.2016.12.014] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2016] [Revised: 12/28/2016] [Accepted: 12/29/2016] [Indexed: 11/27/2022]
Abstract
Mycotic aortic aneurysm is a rare and challenging complication of aortic homografts caused by an infection and is associated with high morbidity and mortality. We report the first case of an aortic cross homograft mycotic pseudoaneurysm caused by Robinsoniella peoriensis in a 70-year-old man. Our patient underwent surgery for a recurrence of aortic cross mycotic pseudoaneurysm at the level of the aortic homograft he had had 7 years before. A clot-removal of the pseudoaneurysm was surgically carried out and the homograft was completely removed. Anaerobic culture from tissue samples yielded pure growth of a spore-forming Gram-positive rod, identified later as Robinsoniella peoriensis by 16S rRNA gene sequencing. The patient was then discharged with oral clindamycin according to the in vitro susceptibility testing. Identification of R. peoriensis might be challenging in clinical laboratories with no access to molecular methods.
Collapse
Affiliation(s)
- H Mertes
- Cliniques Universitaires St. Luc, Internal Medicine and Infectious Diseases Department, Avenue Hippocrate 10, 1200 Brussels, Belgium.
| | - L Defourny
- Cliniques Universitaires St. Luc, Clinical Microbiology Department, Avenue Hippocrate 10, 1200 Brussels, Belgium
| | - M Tré-Hardy
- Cliniques Universitaires St. Luc, Clinical Microbiology Department, Avenue Hippocrate 10, 1200 Brussels, Belgium
| | - R Lhommel
- Cliniques Universitaires St. Luc, Nuclear Medicine Department, Avenue Hippocrate 10, 1200 Brussels, Belgium
| | - G El Khoury
- Cliniques Universitaires St. Luc, Cardiovascular Surgery Department, Avenue Hippocrate 10, 1200 Brussels, Belgium
| | - H Rodriguez-Villalobos
- Cliniques Universitaires St. Luc, Clinical Microbiology Department, Avenue Hippocrate 10, 1200 Brussels, Belgium
| | - L Belkhir
- Cliniques Universitaires St. Luc, Internal Medicine and Infectious Diseases Department, Avenue Hippocrate 10, 1200 Brussels, Belgium
| |
Collapse
|
28
|
Tré-Hardy M, Saussez T, Yombi JC, Rodriguez-Villalobos H. First case of a dog bite wound infection caused by Streptococcus minor in human. New Microbes New Infect 2016; 14:49-50. [PMID: 27688883 PMCID: PMC5031475 DOI: 10.1016/j.nmni.2016.08.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2016] [Revised: 08/01/2016] [Accepted: 08/05/2016] [Indexed: 11/27/2022] Open
Abstract
We report the first case of human infection caused by Streptococcus minor in a 51-year-old immunocompetent woman admitted for dog bite injuries. At present, the role of Streptococcus minor in bite wound infections is unknown. Further studies on virulence factors are needed to elucidate its pathogenicity mechanisms.
Collapse
Affiliation(s)
- M Tré-Hardy
- Department of Microbiology, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium
| | - T Saussez
- Department of Urology, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium
| | - J C Yombi
- Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium
| | - H Rodriguez-Villalobos
- Department of Microbiology, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium
| |
Collapse
|
29
|
Tré-Hardy M, Capron A, Antunes MV, Linden R, Wallemacq P. Fast method for simultaneous quantification of tamoxifen and metabolites in dried blood spots using an entry level LC-MS/MS system. Clin Biochem 2016; 49:1295-1298. [PMID: 27498307 DOI: 10.1016/j.clinbiochem.2016.07.018] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2016] [Revised: 07/27/2016] [Accepted: 07/28/2016] [Indexed: 01/14/2023]
Abstract
The purpose of this study was to develop and validate a new liquid chromatography-tandem mass spectrometric (LC-MSMS) assay for the simultaneous quantification of tamoxifen (TAM) and its main therapeutically active metabolites, N-desmethyltamoxifen (NDT), 4-hydroxytamoxifen (4HT) and endoxifen (END) in dried blood spots. Ultrasound assisted methanolic extraction was used for TAM and metabolites extraction from dried blood spot. After evaporation and methanol reconstitution, the extract was injected into a LC-MSMS system. Reversed phase chromatography was performed on a C18 grafted column in gradient mode. TAM, metabolites, and internal standard (diazepam-d5; IS) were identified in positive electrospray ionization mode using m/z transition of 372.5>72.1 (TAM); 374.23>58.10 (END); 358.27>58.10 (NDT); 388.23>44.80 (4HT) and 290.00>198.00 (IS). Total analytical run time was 6.5min. Assay was linear from 1 to 500ng/mL for all substances and presented intra and inter-assay precision and accuracy <15%. TAM, NDT, 4HT and END limits of quantification and detection were of 1 and 0.5ng/mL; 1 and 3ng/mL; 1.7 and 3ng/mL; 0.6 and 2ng/mL, respectively. Recovery ranged from 83.8 to 96.3% with matrix effect ranged from 4.3 to 29.8% for TAM and its metabolites. Hematocrit value ≤40% appeared to negatively influence accuracy of the method. In conclusion, the method described here is somewhat accessible, relatively fast, sensitive and selective with no interference. This assay might be used to investigate the level of TAM and its metabolites in DBS for therapeutic drug monitoring purposes.
Collapse
Affiliation(s)
- Marie Tré-Hardy
- Clinical Chemistry Department, Cliniques universitaires St Luc, Brussels, Belgium
| | - Arnaud Capron
- Clinical Chemistry Department, Cliniques universitaires St Luc, Brussels, Belgium; Louvain Center for Toxicology and Applied Pharmacology, Université catholique de Louvain, UCL, Brussels, Belgium
| | | | - Rafael Linden
- Instituto de Ciências da Saúde, Universidade Feevale, Novo Hamburgo, RS, Brazil
| | - Pierre Wallemacq
- Clinical Chemistry Department, Cliniques universitaires St Luc, Brussels, Belgium
| |
Collapse
|
30
|
Tré-Hardy M, Traore H, El Manssouri N, Vanderbist F, Vaneechoutte M, Devleeschouwer MJ. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents 2009; 34:370-4. [PMID: 19505804 DOI: 10.1016/j.ijantimicag.2009.04.010] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2008] [Revised: 04/17/2009] [Accepted: 04/20/2009] [Indexed: 11/30/2022]
Abstract
Pseudomonas aeruginosa colonisation and chronic lung infection associated with biofilm formation is a major cause of morbidity and mortality in cystic fibrosis (CF) patients. There is thus an urgent need to develop alternative ways to treat biofilm-associated clinical infections. A kinetic study of twice-daily co-administration of the antibiotics tobramycin and clarithromycin was performed over 28 days on 12-day-old mature P. aeruginosa biofilms formed on microplate pegs for 23 clinical isolates of various phenotypes and genotypes to simulate the treatment of CF patients with inhaled tobramycin through aerosolisation (TOBI). Drug activity was assessed by enumeration of persistent bacteria before, during and after treatment. A mature (12-day-old) biofilm model was chosen because a previous study suggested that such a biofilm was a more realistic in vitro model than a 24-h-old biofilm. Synergistic activity of the drug combination was confirmed on biofilms of 9/23 P. aeruginosa isolates. Of these nine isolates, total destruction of the biofilm was observed for five of them. Combination treatment was superior or equivalent to treatment with tobramycin alone, as activity was observed on 47.8% of the isolates with the combination versus 26.1% with tobramycin alone. No correlation was observed between drug susceptibility profiles and the phenotype or genotype of the isolates.
Collapse
Affiliation(s)
- Marie Tré-Hardy
- Pharmaceutical Microbiology Laboratory, Institute of Pharmacy, Université Libre de Bruxelles, CP 205/02, Bd. du Triomphe, 1050 Brussels, Belgium.
| | | | | | | | | | | |
Collapse
|
31
|
Tré-Hardy M, Vanderbist F, Traore H, Devleeschouwer MJ. In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures. Int J Antimicrob Agents 2008; 31:329-36. [DOI: 10.1016/j.ijantimicag.2007.12.005] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2007] [Revised: 12/05/2007] [Accepted: 12/06/2007] [Indexed: 10/22/2022]
|